Synovial Sarcoma, X Breakpoint 2B (SSX2B) (C-Term) anticorps

N° du produit ABIN7217912

Cet anticorps anti-Synovial Sarcoma, X Breakpoint 2B Polyclonal Lapin (ABIN7217912) détecte spécifiquement Synovial Sarcoma, X Breakpoint 2B dans WB, ELISA, IF et IHC. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Synovial Sarcoma, X Breakpoint 2B (SSX2B) (C-Term) anticorps (ABIN7217912)

Antigène: Synovial Sarcoma, X Breakpoint 2B (SSX2B)

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Inconjugué

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC)

Détail du produit

Épitope: C-Term

Fonction: Rabbit Anti-SSX Polyclonal Antibody

Specificité: SSX Polyclonal Antibody detects endogenous levels of SSX protein.

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Immunogène: Synthesized peptide derived from the C-terminal region of human SSX

Isotype: IgG

Information d'application

Indications d'application: Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,IHC: 1:100-300,ELISA 1:20000,IF 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Date de péremption: 12 months

Détail du antigène

Antigène: Synovial Sarcoma, X Breakpoint 2B (SSX2B)

Autre désignation: SSX

Sujet: SSX1, Protein SSX1, Cancer/testis antigen 5.1, CT5.1, Synovial sarcoma, X breakpoint 1, SSX2, SSX2A, SSX2B, Protein SSX2, Cancer/testis antigen 5.2, CT5.2, Synovial sarcoma, X breakpoint 2, Tumor antigen HOM-MEL-40, SSX3, Protein SSX3, Cancer/testis antigen 5.3, CT5.3, SSX4, SSX4A, SSX4B, Protein SSX4, Cancer/testis antigen 5.4, CT5.4, SSX5, Protein SSX5, SSX6, Putative protein SSX6, SSX7, Protein SSX7, SSX8, Protein SSX8, SSX9, Protein SSX9The product of SSX1 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX2 and SSX4 family members, have been involved in t(X,18)(p11. ,q11. ) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome X.

Poids moléculaire: 25kD

ID gène: 6756

UniProt: Q16384